Tags

Type your tag names separated by a space and hit enter

Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
J Clin Lab Anal 2019; 33(8):e22978JC

Abstract

OBJECTIVE

This study aimed to investigate the clinical significance of Krebs von den Lungen-6 (KL-6) serum levels in patients with anti-MDA5 antibody-positive dermatomyositis (anti-MDA5+ DM) having interstitial lung disease (ILD), especially in the amyopathic DM phenotype.

METHODS

The serum KL-6 level was measured using a chemiluminescence enzyme immunoassay (CLEIA) in patients with anti-MDA5+ DM, including clinically amyopathic dermatomyositis (CADM)-ILD and classic DM-ILD, and healthy donors. The baseline and post-treatment serum KL-6 levels were determined in 39 patients with CADM-ILD who experienced remission or acute exacerbation. The association between laboratory findings, high-resolution computed tomography (HRCT) scores, pulmonary function tests (PFTs), and the predictive value of baseline KL-6 level for death was analyzed.

RESULTS

The serum KL-6 levels were significantly higher in patients with CADM-ILD (1339 ± 1329 U/mL) compared with DM-ILD (642.3 ± 498.4 U/mL) and healthy donors (162.4 ± 54.01 U/mL). The KL-6 levels correlated positively with chest HRCT scores, serum lactate dehydrogenase, serum ferritin levels, and PFTs, but not with erythrocyte sedimentation rate. During follow-up, the post-treatment serum KL-6 levels significantly reduced in the remission/stable group, but increased in the acute exacerbation group. Higher levels of ferritin and KL-6 and HRCT scores were independently associated with poor prognosis. The 1-year survival rate was significantly lower in patients with high KL-6 level than in those with low KL-6 level.

CONCLUSION

The serum KL-6 levels may be a useful marker for predicting and monitoring ILD in Chinese patients with anti-MDA5+ DM, especially amyopathic DM phenotype.

Authors+Show Affiliations

Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31301087

Citation

Ye, Yan, et al. "Serum KL-6 Level Is a Prognostic Marker in Patients With anti-MDA5 Antibody-positive Dermatomyositis Associated With Interstitial Lung Disease." Journal of Clinical Laboratory Analysis, vol. 33, no. 8, 2019, pp. e22978.
Ye Y, Fu Q, Wang R, et al. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease. J Clin Lab Anal. 2019;33(8):e22978.
Ye, Y., Fu, Q., Wang, R., Guo, Q., & Bao, C. (2019). Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease. Journal of Clinical Laboratory Analysis, 33(8), pp. e22978. doi:10.1002/jcla.22978.
Ye Y, et al. Serum KL-6 Level Is a Prognostic Marker in Patients With anti-MDA5 Antibody-positive Dermatomyositis Associated With Interstitial Lung Disease. J Clin Lab Anal. 2019;33(8):e22978. PubMed PMID: 31301087.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease. AU - Ye,Yan, AU - Fu,Qiong, AU - Wang,Ran, AU - Guo,Qiang, AU - Bao,Chunde, Y1 - 2019/07/13/ PY - 2019/02/28/received PY - 2019/06/26/revised PY - 2019/06/26/accepted PY - 2019/7/14/pubmed PY - 2019/7/14/medline PY - 2019/7/14/entrez KW - KL-6 KW - anti-MDA5+ dermatomyositis KW - clinically amyopathic dermatomyositis KW - interstitial lung disease KW - serum marker SP - e22978 EP - e22978 JF - Journal of clinical laboratory analysis JO - J. Clin. Lab. Anal. VL - 33 IS - 8 N2 - OBJECTIVE: This study aimed to investigate the clinical significance of Krebs von den Lungen-6 (KL-6) serum levels in patients with anti-MDA5 antibody-positive dermatomyositis (anti-MDA5+ DM) having interstitial lung disease (ILD), especially in the amyopathic DM phenotype. METHODS: The serum KL-6 level was measured using a chemiluminescence enzyme immunoassay (CLEIA) in patients with anti-MDA5+ DM, including clinically amyopathic dermatomyositis (CADM)-ILD and classic DM-ILD, and healthy donors. The baseline and post-treatment serum KL-6 levels were determined in 39 patients with CADM-ILD who experienced remission or acute exacerbation. The association between laboratory findings, high-resolution computed tomography (HRCT) scores, pulmonary function tests (PFTs), and the predictive value of baseline KL-6 level for death was analyzed. RESULTS: The serum KL-6 levels were significantly higher in patients with CADM-ILD (1339 ± 1329 U/mL) compared with DM-ILD (642.3 ± 498.4 U/mL) and healthy donors (162.4 ± 54.01 U/mL). The KL-6 levels correlated positively with chest HRCT scores, serum lactate dehydrogenase, serum ferritin levels, and PFTs, but not with erythrocyte sedimentation rate. During follow-up, the post-treatment serum KL-6 levels significantly reduced in the remission/stable group, but increased in the acute exacerbation group. Higher levels of ferritin and KL-6 and HRCT scores were independently associated with poor prognosis. The 1-year survival rate was significantly lower in patients with high KL-6 level than in those with low KL-6 level. CONCLUSION: The serum KL-6 levels may be a useful marker for predicting and monitoring ILD in Chinese patients with anti-MDA5+ DM, especially amyopathic DM phenotype. SN - 1098-2825 UR - https://www.unboundmedicine.com/medline/citation/31301087/Serum_KL_6_level_is_a_prognostic_marker_in_patients_with_anti_MDA5_antibody_positive_dermatomyositis_associated_with_interstitial_lung_disease_ L2 - https://doi.org/10.1002/jcla.22978 DB - PRIME DP - Unbound Medicine ER -
Unbound Prime app for iOS iPhone iPadUnbound PubMed app for AndroidAlso Available:
Unbound MEDLINE
Unbound PubMed app for Windows